Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Anavex Life Sciences Corp.'s Worst Moves in 2016 So Far

By Cory Renauer - Aug 15, 2016 at 9:24AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Here are a few missteps that might push the filing of a new drug application for its Alzheimer's disease candidate further into the future.

Image source: Getty Images.

Clinical-stage biotech Anavex Life Sciences ( AVXL 3.47% ) made a huge mistake last fiscal year that led to a recent implosion. In December 2014, the company began a phase 2 trial with its lead Alzheimer's disease candidate, 2-73, to determine a safe dosage for use in later studies. The 32-patient trial also included efficacy tests, such as the mini-mental state exam (MMSE), but lacked a control group for comparison.

While the trial will probably succeed at finding a safe dosage, all eyes were on the efficacy data. The stock plunged more than 50% in response to this minor decline in average MMSE scores at the 31-week interim of a 52-week trial. 

Image source: Anavex Life Sciences.

The observed MMSE decline from baseline scores isn't that bad, considering the mix of mild to moderate patients. If patients in a control arm had declined significantly further, the stock probably would have moved in the opposite direction, making this one of the worst blunders of Anavex's last fiscal year.

The safety data will probably be enough to allow a larger, randomized, placebo-controlled trial for 2-73 intended to support applications for treatment of Alzheimer's disease at some point in the future, but when that trial might begin is anybody's guess. The company still hasn't announced a partner, and its own financing options are looking grim. Worse still, Anavex hasn't had a flawless 2016 either -- let's look at some recent blunders that might lead to another market meltdown.

Lopsided spending

Most biotechs in their first year as a public company (Anavex was on the Pink Sheets for years but uplisted to the Nasdaq exchange last year) focus their limited resources into developing new drug candidates they can outlicense or commercialize themselves to begin generating revenue as quickly as possible.

Anavex hasn't been operating as most clinical-stage biotechs. During the nine months ended in June, the company recorded about $6.1 million in general and administrative (or G&A) expenses, more than twice its research-and-development (or R&D) outlay of $2.9 million. At this pace, the company's R&D expenses this year will barely exceed CEO Christopher Missling's total compensation of $3.74 million in 2015.

Over the past decade, a measly 15.3% of new drug candidates with phase 2 successes eventually earned approval. Not planning for the worst is a tremendous risk in any disease area, but Alzheimer's is especially perilous since there are zero long-term disease-modifying successes to date.

Given the dismal odds of scoring with a first shot on goal, advancing additional candidates into early clinical (human) testing creates a crucial safety net. Spending twice as much on G&A than R&D isn't a step in that direction.

Get out of the (rented) lab, already

Bringing candidates to a stage where you can suggest it works in a test tube is relatively easy, but it isn't free. The most disturbing aspect of Anavex's extensive laboratory program is that it lacks a laboratory. At the end of June, the Manhattan-headquartered company reported long-term assets worth just $506, which is probably less than the cost of the device you're using to read this. 

Anavex is pursuing more indications for 2-73 and additional drug candidates but hasn't developed anything further than bare minimums for issuing press releases. Since beginning the 32-patient trial with 2-73 in December, 2014, it has touted preclinical (non-human) data suggesting 2-73 has potential in Rett syndrome, infantile spasms, and autism. It's also announced preclinical data suggesting another candidate, 3-71 has potential in Alzheimer's or other dementias.

In financial statements, Anavex disclosed preclinical data that suggests a third candidate, 1-41, has neuroprotective properties, and a fourth, 1037 might play a role in prostate cancer.

Anavex hasn't started any human trials with 2-73 in the three non-Alzheimer's indications with preclinical data, and it hasn't announced, or disclosed, any investigational new drug applications (a requirement to begin human testing) for 3-71, 1-41, or 1037.

Shunning investors

A lack of financing could explain the need to rent laboratory space and the reluctance to begin more clinical trials. If that's the case, shunning potential investors is the worst move of all. Anavex is the only Nasdaq-listed biotech I know of that doesn't conduct conference calls with investment bank analysts to discuss quarterly earnings reports.

Investment banks generally want to remain on good terms with companies that might pay for their services in the future, and their analysts typically lob puffball questions at management during earnings calls. Not submitting itself to this limited level of scrutiny each quarter is a bad move for a company in desperate need of financing.

It's not all bad

There were some flecks of good news in the company's recent earnings report. Anavex is looking forward to updating a clinical development plan for an eventual phase 2 trial with 2-73 in Rett syndrome. A firm timeline would be nice, but at least it's looking in the right direction.

Perhaps the best disclosure in the recent earnings release is news that Securities and Exchange Commission staff advised Anavex's legal counsel that it did not intend to recommend enforcement action in connection with a formal investigation the regulator began last December.

Anavex may have dodged a big legal bullet, but I don't think now is a good time to begin a long position in the troubled biotech. Staying on the sidelines until it secures enough financing to advance another candidate into clinical trials, or prove 2-73 can beat a placebo in Alzheimer's disease or another indication, could save you a bundle.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Anavex Life Sciences Corp. Stock Quote
Anavex Life Sciences Corp.
AVXL
$18.61 (3.47%) $0.62

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
633%
 
S&P 500 Returns
140%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/07/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.